Registrations to the Boehringer Academy
Increasing Demand For Online CPD During COVID-19 Pandemic
4 years ago 
1297 views
Over 400 veterinary professionals in the UK and Ireland took part in a survey last month conducted by Boehringer Ingelheim Animal Health UK Ltd. As part of the company’s ongoing commitment to support the veterinary profession, clients and pets/livestock during the current COVID-19 pandemic, the survey sought to understand what additional support veterinary professionals needed at this time. The most requested support service by 71% of respondents was for the provision of online CPD for learning whilst at home.
The results of the survey are backed up by the number of vets registering for, and using the Boehringer Academy, the company’s free-to-use online CPD platform.
“We’ve seen an 86% increase in the amount of Boehringer Academy CPD consumed in March 2020 compared to the previous month, and an 87% increase in month-on-month registrations over the same period” says Boehringer Ingelheim’s Digital Asset Manager; James Michell.
The Boehringer Academy provides unlimited access to a vast selection of high quality, relevant CPD across a multitude of animal health topics including small animal, equine, ruminant and swine. The Academy also features non-clinical CPD focused on topics such as executive coaching, mindfulness and wellbeing. Content is available as webinars, short videos, podcasts and articles, and can be accessed 24/7 via desktop, mobile and tablet, making it a very flexible learning tool for many differing lifestyles. Vets, vet nurses, practice managers and front of house staff can gain instant, free access to the resources available on the Boehringer Academy by registering at www.boehringer-academy.co.uk.
Ends
Boehringer Ingelheim Animal Health UK Ltd Business Unit
Boehringer Ingelheim is the second largest animal health business in the world. We are committed to creating animal wellbeing through our large portfolio of advanced, preventive healthcare products and services. With net sales of €3.9 billion and around 10,000 employees worldwide, we are present in more than 150 markets. For more information visit www.boehringer-ingelheim.com/animal-health/overview.
More from Boehringer Ingelheim
- Boehringer Ingelheim receives FDA approval for SENVELGO® (velagliflozin oral solution): the first oral liquid medication for diabetes in cats
- Boehringer Ingelheim Animal Health launches new ProZinc webinar and toolkit
- NexGard Spectra ‘Yum and Done’ competition winner announced
- Boehringer Ingelheim launches Parassess - a “first-of-its-kind”, online, personalised dog parasite risk checker
- ABCD & Boehringer Ingelheim invite applications for the 2022 Young Scientist Award
20 hours ago